ARKG ETF Analysis: ARK Genomic Revolution | BATS
Health | BATS, USA | Market Cap: 1.260m USD | 12M Return: 52.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 168M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ARKG is an actively-managed, non-diversified exchange-traded fund that focuses on companies involved in the genomics revolution. The fund invests at least 80% of its assets in domestic and foreign equity securities spanning multiple sectors, including healthcare, information technology, materials, energy, and consumer discretionary. By targeting a specific investment theme rather than a broad market segment, the fund takes a thematic approach to identifying companies whose businesses are tied to advances in genomics-related technologies.
The genomics sector encompasses a range of business activities, including gene sequencing, gene editing (such as CRISPR-based technologies), molecular diagnostics, bioinformatics, and personalized medicine. Companies in this space typically work at the intersection of biotechnology and data science, with applications spanning human health, agriculture, and industrial biotechnology. Because ARKG is non-diversified, it may hold concentrated positions within these genomics-related areas rather than spreading investments broadly across industries.
- CRISPR gene therapy approvals drive top holdings revenue growth
- FDA gene editing regulation tightens delaying clinical trial timelines
- Liquid biopsy competition intensifies pressuring Exact Sciences margins
- ARK fund outflows accelerate as genomics sentiment weakens
As of July 21, 2026, the stock is trading at USD 38.28 with a total of 3,988,038 shares traded. Over the past week, the price has changed by -5.69%, over one month by +5.16%, over three months by +22.54% and over the past year by +52.33%.
Current recommended Stop Loss: 36.20 (which is 5.4% or 1.3 ATR below the current price).
ARK Genomic Revolution has no consensus analysts rating.